期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

紫杉醇药性

Study of Taxol Four Properties of Traditional Chinese Medicine
原文传递
导出
摘要 紫杉醇被广泛用于临床治疗肿瘤类疾病。根据紫杉醇植物特性、临床用药范围及毒副作用等特点,将紫杉醇定性为凉而非寒的药物,为临床辨证用药提供参考。 Paclitaxel as a contemporary chemotherapy medicine,is widely used in clinical treatment of tumor diseases. We start from the theory of traditional Chinese medicine,according to the characteristics of the plant characteristics,paclitaxel clinical medicines and side effect of the drug,paclitaxel as a cool but not cold medicine,so as to provide reference for clinical TCm drugs.
作者 张聪
机构地区 成都中医药大学肿瘤科
出处 《实用中医内科杂志》 2014年第3期55-56,共2页 Journal of Practical Traditional Chinese Internal Medicine
关键词 紫杉醇 中药四性 方药纵横 Paclitaxel Four properties of traditional Chinese medicine Medicine aspect
分类号 R282.7 [医药卫生—中药学] R285 [医药卫生—中药学]
  • 相关文献

参考文献10

  • 1顾观光.神农农本草经[M].北京:学苑音像出版社,2002.
  • 2元·王好古.汤液本草[M].北京:福中国中医药出版社,2008:3-4.
  • 3廖希雍.神农本草经疏[M].北京:中国医药科技出版社,2011:2-4.
  • 4ABU-KHALAFm m, JUNEJAV, CHUNG G G, etal.Long- term assessment of cardiac function after dose-dense and -intense sequential doxorubicin ( A ), paclitaxel ( T ), and cyelophospham ide ( C ) adjuvant therapy for high risk breast cancer [ J ] .Breast Cancer Res Treat, 2007, 104 (3) : 341.
  • 5孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
  • 6李时珍.本草纲目[M].成都:四川科学技术出版社,2008.
  • 7张景岳著,范志霞校注.类经[M].北京:中国中医药出版社,2011:427.
  • 8鲁艳春,陈多才.紫杉醇心脏毒性的临床观察[J].中国医疗前沿,2010,5(18):49-50. 被引量：7
  • 9刘克成,高文斌,马海英,尹良伟.紫杉醇化疗心脏毒性评价[J].医学研究通讯,2004,33(6):60-60. 被引量：2
  • 10杨兴艳,薛月珍.紫杉醇心脏毒性研究进展[J].医药导报,2009,28(8):1064-1067. 被引量：21

二级参考文献31

  • 1宋颖秋,李贵玲,石星,张盛,王晶,尹中元.紫杉醇联合顺铂治疗复发性宫颈癌的临床观察[J].肿瘤基础与临床,2006,19(5):383-384. 被引量：8
  • 2GELDERBLOM H, VERWEI J J, NOOTER K,et al. The drawbacks and advantages of vehicle selection for drug formulation [ J ]. Eur J Cancer,2001,37(13) :1590.
  • 3ABU-KHALAF M M, JUNEJ A V, CHUNG G G,et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T) , and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer [J]. Breast Cancer Res Treat.2007.104 (3) ,341.
  • 4ARMSTRONG D K, BOOKMAN M A, MCGUIRE W,et al. A phase I study of paclitaxel, topotecan, cisplatin and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study [ J ]. Gynecol Oncol, 2007, 105 (3) :667.
  • 5PERKINS C L, FANG G, KIM C N. The role of Apaf-1, caspase-9, and bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis[ J]. Cancer Res,2000,60 (6) :1645.
  • 6SYMMANS W F, VOLOM M D, SHAPIRO R L, et al. Paclitaxelinduced apoptosis and mitotic arrest assessed by serial fine-needle aspiration : implications for early prediction of breast cancer response to neoadjuvant treatment[J]. Clin Cancer Res,2000 ,6 (12) :4610.
  • 7KLAUBER N, PARANGI S, FLYNN E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2- methoxyestradiol and taxol [ J ]. Cancer Res, 1997,57 ( 1 ) : 81.
  • 8PARK D C, KI J H, LEW Y O, et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[ J ]. Gynecol Oncol, 92(1) :59.
  • 9DAVID H, MOORE J A,BLESSING R P,et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study [ J ]. J Clin Oncol, 2004,22 ( 15 ) : 3113.
  • 10BUDA A , ROLDANO F, NICOLETTA C,et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study [ J]. J Clin Oncol,2005,23(18) :4137.

共引文献329

实用中医内科杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部